

Author Index

- Abernathy, M. P., 260
 Abu-Saad, H. H., 402
 Anand, K. J. S., 347, 417, 425
 Andiman, W. A., 72
 Andrews, W. W., 242
 Athanassiou, A. M., 166
 Avery, G. B., 216
- Bacq, Y., 134
 Baltimore, R. S., 1, 25
 Beazley, D. M., 332
 Blanco, J. D., 251
 Bours, G. J. J. W., 402
 Brown, H. L., 260
- Casale, H. L., 149
 Chapman, S. J., 339
 Chervenak, F. A., 183, 184
 Connolly, T. J., 178
 Cox, S. M., 323
 Craigo, S. D., 97, 156, 166
- D'Alessio, J. G., 350
 Davidson, K. M., 104
 Duff, P., 241, 277
- Egerman, R. S., 332
 Evans, M. I., 189
- Fleischman, A. R., 183, 184
 Fletcher, J. C., 189
 Foster, N., 223
 Franck, L. S., 434
- Garner, P. R., 445, 446
 Gates, E. A., 233
 Goldworth, A., 198
- Hague, W. M., 497
 Hamers, J. P. H., 402
 Hollier, L. M., 323
- Iams, J. D., 267
 Infante, A. J., 2
- Jacobs, R. F., 64
 Jenson, H. B., 1, 50
- Kaftan, H., 15
 Keely, E., 471
 Kimberlin, D. F., 242
 Kinney, J. S., 15
 Knox, T. A., 98
 Kraybill, E. N., 207
 Kurth, C. D., 390
- Laifer, S. A., 149
 Lawhon, G., 434
 Lerman, J., 363
- McCullough, L. B., 183, 184
 McIntosh, N., 417
 McKenna, D. S., 267
 Magriples, U., 112
 Markenson, G. R., 309
 Mellor, D. J., 363
 Menon, G., 417
- Mestman, J. H., 485
 Minkoff, H. L., 293
 Molitch, M. E., 457
- O'Hara, I. B., 390
- Pollock, B. H., 50
- Ralston, S. J., 141
 Ramanathan, J., 350
 Repke, J. T., 118
 Riggs, J. W., 251
 Riley, L. E., 284
 Rosa, C., 318
 Russell, M. A., 156
- Saphier, C. J., 118
 Schelonka, R. L., 2
 Schwaitzberg, S. D., 141
 Sethna, N., 380
 Siegel, J. D., 33
 Spaeth, J. P., 390
 Stevens, B., 402
 Stevenson, D. K., 198
 Suresh, S., 425
- Terry, A. J., 497
- Welliver, R. C., 87
- Yancey, M. K., 309
- Zuckerman, A. L., 178

Subject Index

- Abortion
 elective, following prenatal diagnosis, 191-194
 spontaneous, *see* Spontaneous abortion
 Acetaminophen, 377, 386, 387, 397, 421
 Acquired immunity, neonatal, 5-10
 molecular basis of diversity in, 5-6
 T cells, *see* T cell(s), neonatal
 TCRs in, *see* T cell receptors, neonatal
 Acquired immunodeficiency syndrome, *see* HIV
 infection, neonatal; HIV infection in
 pregnant women
 Acromegaly in pregnancy, 463-464
 ACTH (adrenocorticotropin hormone;
 corticotropin), normal ranges of plasma, in
 pregnancy, 447
 Activation
 of neonatal B cells, 10
 of neonatal T cells, 6-9
 Active hepatitis, chronic, in pregnancy, therapy of,
 115-116
 Acute fatty liver of pregnancy (AFLP), 134-140
 biochemical findings in, 135-136
 clinical characteristics of, 120, 135-136
 etiology of, 136-137
 management of, 138
 maternal and fetal outcome with, 136
 pathology of, 134-135
 preeclampsia, HELLP syndrome and, 137-138
 Acute (episodic) pain, neonatal, chronic versus, 418-
 419
 Acute Sheehan's syndrome, 465-466
 Addiction, defined, 425
 Adherence of neutrophils, 3
 Adrenal hyperplasia, *see* Congenital adrenal
 hyperplasia in pregnancy
 Adrenalectomy
 for CAH, 453
 for primary hyperaldosteronism, 475
 α -Adrenergic blockers, 478
 β -Adrenergic blockers, 474, 475, 477, 478
 Adrenocorticotropin hormone (ACTH;
 corticotropin), normal ranges of plasma, in
 pregnancy, 447
 Adverse effects
 cutaneous, of EMLA cream, 386
 of opioids, neonatal opioid tolerance and, 427
 see also therapeutic modalities
 AFLP, *see* Acute fatty liver of pregnancy

- AIDS (acquired immunodeficiency syndrome), *see*
HIV infection, neonatal; HIV infection in
pregnant women
- Airway management in general anesthesia for
neonatal emergency surgery, 365-368
- Alcoholic liver disease, contraception for patients
with, 181
- Aldomet, 475, 477
- Alfentanil, 358, 372-373, 421, 422
- Aminoglutethimide, 481
- Amsel criteria for BV diagnosis, 244
- Analgesia, neonatal
following general anesthesia for neonatal
emergency surgery, 377-378
see also Analgesia and sedation in NICUs;
Environmental and behavioral pain
interventions in NICUs; Measures of neonatal
pain; Opioid tolerance in neonates; Regional
anesthesia and analgesia, neonatal
- Analgesia and sedation in NICUs, 417-424
and characteristics of pain, *see* Pain
clinical approach to, 423
nonpharmacological methods of, 420, 421
systemic, 420-422
topical, 420
- Anemia, chronic, parvovirus B19 infection and, 311-
312
- Anesthesia, *see* Neonatal anesthesia
- Aneurysm, splenic artery, as complication of
cirrhosis and portal hypertension in
pregnancy, 162-163
- Angioplasty, percutaneous transluminal, of
renovascular hypertension, 474
- Antenatal conditions and interventions, *see* Fetus
- Antibiotics
for BV, 247, 248
for cirrhosis-related ascites, 163
for LAI infection, 253, 255
for neonatal GBS infection, 33-34, 271, 273
in prevention of toxoplasmosis, 335
resistance to, as risk factor for nosocomial
infections in NICUs, 29-30
for syphilis, 327-329
see also Antibiotics, prophylaxis of neonatal GBS
infections with
- Antibiotics, prophylaxis of neonatal GBS infections
with, 37-46
intrapartum, 39-46
maternal, 37
neonatal, 271, 273
postnatal, 37-38
- Antibodies
classes and subclasses of, 10-11
general structure of, 10
RSV, in prevention of RSV infection, 88, 90-92
- Antiretroviral therapy of HIV-infected pregnant
women, 74-79, 84, 295, 300, 302-304
- Antisepsis, vaginal, in prevention of neonatal GBS
infections, 37
- Arginine-vasopressin (AVP; vasopressin), and water
balance in pregnancy, 467
- Ascites, as complications of cirrhosis and portal
hypertension in pregnancy, 163
- Assessment, *see* Diagnosis
- Atracurium, 356, 373-375
- Atropine, 363, 371, 373, 375, 398, 419
- Autonomy principle, futility of care considerations
in NICUs and, 217-218
- AVP (arginine-vasopressin; vasopressin), and water
balance in pregnancy, 467
- Azathioprine (AZA) in pregnant liver transplant
recipient, 150-151
- Azidothymidine (zidovudine; AZT) for HIV
infection, 75-79, 84, 295, 300, 302-304
- B cells, neonatal, 10-11
- Baby Doe regulations, futility of care considerations
in NICUs and, 218
- Bacterial vaginosis (BV), 242-250
diagnosis of, 243-244
historical perspective on, 242
incidence of, 242
microbiology of, 243
and normal vaginal flora, 242-243
preterm birth and delivery and, *see* Preterm birth
and delivery, BV and
therapy of, 247-248
- Behavior Pain Score (BPS), neonatal pain
assessment with, 405, 406
- Behavioral pain interventions in NICUs, *see*
Environmental and behavioral pain
interventions in NICUs
- Benign neoplasms of liver in pregnancy, 169-171
- Benzocaine, 386
- Best interest of infant consideration, as ethical issue
in delivery room, 201, 204-205
- Biliary cirrhosis, primary, contraception for patients
with, 180
- Biochemical findings on liver disease(s) in
pregnancy
on abnormal liver function, 101-102
on AFLP, 135-136
see also Laboratory evaluation and specific conditions
- Birth canal microorganisms, early onset neonatal
bacterial infections associated with, 16
- Birth defects, *see* Congenital birth defects
- Birth and delivery, *see* Labor and delivery
- Birth weight
and effectiveness of preventive IVIg, 52-54
see also Low birth weight infants
- Blood cell count, early onset neonatal bacterial
infection diagnosis with, 20-22
- Blood cultures, early onset neonatal bacterial
infection diagnosis with, 17-19
- Blood stream infections, as risk factors for
nosocomial infections in NICUs, 27-28
- BPD (bronchopulmonary dysplasia), *see* Respiratory
syncytial virus infection, neonatal
- BPS (Behavior Pain Score), neonatal pain
assessment with, 405, 406
- Breast milk, *see* Nursing
- Bromocriptine, 459, 461, 462
- Bronchopulmonary dysplasia, *see* Respiratory
syncytial virus infection, neonatal
- Budd-Chiari syndrome, contraception for patients
with, 180

- Bupivacaine, 351, 376-377, 382, 384, 385, 397
Business interests, professional obligations, and managed care of reproductive health, 234
BV, *see* Bacterial vaginosis
- Cabergoline, 459, 462
Caffeine, 377, 381, 397
CAH, *see* Congenital adrenal hyperplasia in pregnancy
Calcium channel blockers, 475
Calcium homeostasis during pregnancy, 485-487; *see also* Parathyroid disorder(s) in pregnancy
Calcium supplementation, 490, 494
Cardiovascular responses to neonatal anesthesia to epidural anesthesia, 384
to spinal anesthesia, 383
Cardiovascular system of micropremies, anesthesia and, 392-393
Care of extremely low birth weight infants, 207-215
decision making in, *see* Decision making in care of extremely low birth weight infants
ethical principles governing, 209-210
infant outcome and, 208
withholding versus withdrawing of life-sustaining care, 213-214
see also Futility of care considerations in NICUs
Catecholamines
physiology of, 476
in pregnancy, 476-477
Catheters, intravascular, and nosocomial infections in NICUs, 28-29
Cell differentiation, B cell, 10
Chemotaxis of neutrophils, 3
Chickenpox, *see* Varicella
2-Chloroprocaine, 384
Chlorpromazine, 431, 432
Chlorpropamide, 467
Cholelithiasis, contraception for patient with, 179-180
Cholestasis of pregnancy, *see* Intrahepatic cholestasis of pregnancy
Chronic active hepatitis in pregnancy, therapy of, 115-116
Chronic anemia, parvovirus B19 infection with, 311-312
Chronic diabetes insipidus (DI), management of, 467
Chronic hypopituitarism, 464-465
Chronic pain, 418-421
acute versus, 418-419
assessment of, 420-421
Chronic Sheehan's syndrome, 465, 466
Circumcision, neonatal, regional anesthesia and analgesia for, 384-387
Cirrhosis
primary biliary, contraception for patients with, 180
see also Cirrhosis and portal hypertension in pregnancy
Cirrhosis and portal hypertension in pregnancy, 156-165
complications of, 161-164
diagnosis of, 157-158
etiology of, 157
fetal and maternal monitoring with, 159-160
incidence of, 157
labor and delivery with, 160
postpartum management in, 160-161
preconception counseling for, 158-159
Classes of Igs and antibodies, 10-11
Clinical course
of ICP, 105-106
see also specific conditions
Clinical features and presentation
of Cushing's syndrome, 479-480
of HSV infection, 286-287
of hypoparathyroidism, 491
of neonatal GBS infections, 35-36
of neonatal opioid withdrawal, 428
of osteoporosis, 493
of pheochromocytoma, 476-477
of PPT, 499-500
of primary hyperaldosteronism, 474-475
of renovascular hypertension, 473
of rubella, 318-319
of rubeola, 321
of Sheehan's syndrome, 465
of syphilis, 324-326
of toxoplasmosis, 333
of VZV infection, 340
see also Clinical features and presentation of CMV infection; Clinical features and presentation of liver disease(s) in pregnancy
Clinical features and presentation of CMV infection, 261-264
fetal, 262-263
maternal, 261-262
neonatal, 263-264
Clinical features and presentation of liver disease(s) in pregnancy
of AFLP, 120, 135-136
of HELLP, 118-119
of liver hematoma and rupture, 142-143
of liver masses, 167
Clinical Scoring System (CSS), neonatal pain assessment with, 405, 406
Clinically nonfunctioning pituitary tumors in pregnancy, 464
Clonidine, 376, 432
CMV infection, *see* Cytomegalovirus infection
Colonization by group B streptococci, 34
COMFORT Scale of neonatal pain, 407, 411
Commensal species, skin, in neonatal nosocomial infections, 27-29
Complement system, neonatal, 4-5
Complications, *see specific conditions and interventions*
Confidentiality
issue of, following prenatal diagnosis, 192
in managed care of reproductive health, 237
Congenital adrenal hyperplasia (CAH) in pregnancy, 446-456
11- β -hydroxylase deficiency, 453-454
21-hydroxylase deficiency, 449-453
3 β -hydroxysteroid dehydrogenase deficiency, 454
hypothalamic-pituitary-adrenal axis in normal pregnancy and, 447-448

- pathophysiology of, 448-449
- Congenital birth defects
 due to parvovirus B19 infection, 313
 see also specific conditions
- Congenital rubella syndrome (CRS), 320
- Congenital syphilis, 325-327
- Congenital varicella (varicella embryopathy), 341-342
- Consent, *see* Informed consent
- Containing and positioning of infant in neonatal pain management, 439
- Continued intensive care decision for all extremely low birth weight infants, 210
- Contraception
 for prolactinoma patient, 462-463
 see also Contraception for liver disease patient
- Contraception for liver disease patient, 178-182
 with alcoholic liver disease, 181
 with cholelithiasis, 179-180
 with HELLP, 128-130
 with hepatitis, 179
 with intrahepatic cholestasis of pregnancy, Wilson's disease, primary biliary cirrhosis, and Budd-Chiari syndrome, 180
 for transplanted patients, 153, 181
- Corticosteroids during pregnancy of liver transplant recipients, 150
- Corticotropin (adrenocorticotropin hormone), normal ranges of plasma, in pregnancy, 447
- Corticotropin-releasing hormone (CRH), physiology of, and changes in, in pregnancy, 479
- Cortisol, normal ranges of plasma-free, urinary-free, and total, in pregnancy, 447
- Cost/benefit analysis of RSVIg therapy, 93-94
- Counseling
 genetic, informed consent and, 190
 of HIV-infected pregnant women, 296
 see also Preconception counseling
- C-reactive protein (CRP) test, early onset neonatal bacterial infection diagnosis with, 22
- CRH (corticotropin-releasing hormone), physiology of, and changes in, in pregnancy, 479
- CRIES, neonatal pain assessment with, 408-409, 411
- CRP (C-reactive protein) test, early onset neonatal bacterial infection diagnosis with, 22
- CRS (congenital rubella syndrome), 320
- CSS (Clinical Scoring System), neonatal pain assessment with, 405, 406
- Cushing's syndrome (hypercortisolemia) in pregnancy, 479-482
- Cutaneous side effects of EMLA cream in neonates, 386
- Cyclosporine for pregnant liver transplant recipients, 151
- Cysts, hepatic, as nonneoplastic liver masses in pregnancy, 175
- Cytolytic activity of neonatal T cells, 7-10
- Cytomegalovirus (CMV) infection, 260-266
 clinical manifestations of, *see* Clinical features and presentation of CMV infection
 epidemiology of, 260-261
 microbiology of, 260
 screening for, and prevention of, 264-265
 therapy of, 265
- dDAVP (desmopressin), 467, 468
- Decision making in care of extremely low birth weight infants, 208-212
 for intensive care, 210-212
 limiting care based on survival probability, 210-211
 parental role in, *see* Parental role in decision making
 problems of, 208-209
 see also Futility of care considerations in NICUs
- Deficient production
 of neonatal IgG, 11
 of neonatal neutrophils, 3-4
- Delivery, *see* Labor and delivery
- Delivery room, ethical consideration(s) in, 198-206
 family members' interests as, 201-202, 204-205
 futility of care as, 202-205; *see also* Futility of care considerations in NICUs
 infant's best interest as, 201, 204-205
 quality of life as, 200-201, 204-205
- Desflurane, 357, 369, 370
- Desmopressin (dDAVP), 467, 468
- Development
 infant, synactive theory of, NIDCAP model and, 435-437
 of neonatal B cells, 10
- Diabetes insipidus (DI) in pregnancy, 467-468
- Diabetes mellitus (DM), as complication of cirrhosis and portal hypertension in pregnancy, 163
- Diagnosis
 of BV, 243-244
 differential, *see* Differential diagnosis
 of IAI, 253-255
 of neonatal opioid tolerance, 428-430
 of rubella, 319
 of rubeola, 321
 of syphilis, 325-327
 of toxoplasmosis, 333-335
 of VZV infection, 340-341
 see also Diagnosis of endocrine disorder(s) in pregnancy; Diagnosis of HIV infection; Diagnosis of HSV infection; Diagnosis of liver disease(s) in pregnancy; Fetal diagnosis; Laboratory evaluation; Measures of neonatal pain; Screening
- Diagnosis of endocrine disorder(s) in pregnancy
 of Cushing's syndrome, 480-481
 of hypoparathyroidism, 491
 of osteoporosis, 492-493
 of pheochromocytoma, 477-478
 of primary hyperaldosteronism, 475
 of renovascular hypertension, 473-474
 see also Differential diagnosis of endocrine disorder(s) in pregnancy
- Diagnosis of HIV infection
 maternal, 73-74, 295-296
 neonatal, 79-82
- Diagnosis of HSV infection
 maternal, 285-286
 neonatal, 65-67
- Diagnosis of liver disease(s) in pregnancy
 of cirrhosis and portal hypertension, 157-158
 differential, of HELLP, 119-121

- of HAV infection, 277
- of HBV infection, 278-279
- of HCV infection, 114, 281
- of HDV infection, 280
- of HEV infection, 115, 282
- of HGV infection, 282
- of liver hematoma and rupture, 142-144
- of liver masses, 167-169
- see also* Biochemical findings on liver disease(s) in pregnancy; Liver function in pregnancy, evaluation of abnormal
- Diazepam, 371, 396, 431
- Differential diagnosis
 - of HELLP, 119-121
 - see also* Differential diagnosis of endocrine disorder(s) in pregnancy
- Differential diagnosis of endocrine disorder(s) in pregnancy
 - of hypercalcemia in hyperparathyroidism, 488-490
 - of hyperprolactinemia, 459
- Direct neonatal effects of maternal regional anesthesia, 351
- Disclosure in managed care of reproductive health, 236-237
- Disseminated disease, neonatal, *see* Herpes simplex virus infections, neonatal
- Distress, defined, 417
- Distress Scale for Ventilated Newborn Infants (DSVNI), 409-410, 412
- Distributive justice, rationing of care and, and futility of care considerations in NICUs, 220-221
- Diversity in neonatal acquired immunity, molecular basis of, 5-6
- DM (diabetes mellitus), as complication of cirrhosis and portal hypertension in pregnancy, 163
- Dorsal penile nerve block for neonatal circumcision, 385
- Dose, EMLA cream, for neonates, 386
- Drug transfer, placental, maternal anesthesia and, 350-351
- DSVNI (Distress Scale for Ventilated Newborn Infants), 409-410, 412
- Dysplasia, bronchopulmonary, *see* Respiratory syncytial virus infection, neonatal
- Early congenital syphilis, 325
- Early onset neonatal bacterial infections, 15-24
 - epidemiology of, 16-17
 - laboratory evaluation of, *see* Laboratory evaluation of early onset neonatal bacterial infections
 - microbiology and pathogenesis of, 15-16
 - see also* Group B streptococcus infections, neonatal; Intravenous immunoglobulin therapy for neonatal sepsis; Nosocomial infections in NICUs
- EI (erythema infectiosum), parvovirus B19 and, 311
- Elective abortion following prenatal diagnosis, 191-194
- Emergence from general anesthesia for neonatal emergency surgery, 377-378
- Emergency surgery, anesthesia for neonatal, 363-379
 - general anesthesia, *see* Emergency surgery, general anesthesia for neonatal
 - regional anesthesia, 376-377
- Emergency surgery, general anesthesia for neonatal, 363-376
 - airway management in, 365-368
 - emergence from, and analgesia following, 377-378
 - fasting prior to, 363
 - fluid and metabolic requirements in, 375-376
 - importance of thermoregulation in, 376
 - monitoring of, 363-365
 - pharmacology of anesthetics used in, *see* Pharmacology of anesthetics used with neonates
 - premedication in, 363
- EMLA cream, 384-387, 419, 420
- Encephalopathy, as complication of cirrhosis and portal hypertension in pregnancy, 162
- Endocrine disorder(s) in pregnancy
 - introduction to, 445
 - see also* Congenital adrenal hyperplasia in pregnancy; Hypertension in pregnancy, endocrine cause(s) of; Parathyroid disorder(s) in pregnancy; Pituitary disease(s) and tumor(s) in pregnancy; Postpartum thyroiditis
- Enflurane, 357, 369
- Enterocolitis, necrotizing, exploratory laparotomy for, in micropremies, anesthesia for, 397-399
- Environmental and behavioral pain interventions in NICUs, 434-443
 - behavioral strategies, 439-442
 - environmental strategies, 437-438
 - synactive theory of infant development and NIDCAP model, 435-437
- Ephedrine, 352-353
- Epidemiology
 - CMV infection, 260-261
 - HIV, 293-294
 - HSV, 285-286
 - toxoplasmosis, 333
 - see also* Epidemiology of liver disease(s) in pregnancy; Epidemiology of neonatal infections; Incidence
- Epidemiology of liver disease(s) in pregnancy
 - of ICP, 104
 - of liver hematoma and rupture, 141
- Epidemiology of neonatal infections
 - early onset infections, 16-17
 - GBS infections, 34-35
 - nosocomial infections in NICUs, 25-26
 - RSV infection, 87-88
- Epidural anesthesia and analgesia, neonatal, 383-384
- Episodic (acute) pain, neonatal, chronic versus, 418-419
- Erythema infectiosum (EI; fifth disease), parvovirus B19 and, 311
- Established pain, *see* Chronic pain
- Ethical issues
 - introduction to, 183
 - see also* Care of extremely low birth weight infants; Delivery room, ethical consideration(s) in; Experimentation, treatment versus; Futility of

- care considerations in NICUs; Physicians, moral obligations of; Reproductive genetics, ethics in; Reproductive health, managed care of
- Ethics committees, and futility of care considerations in NICUs, 218-219
- Etiology
 - of AFLP, 136-137
 - of cirrhosis and portal hypertension in pregnancy, 157
 - see also specific conditions*
- Etomidate, 354-355, 358
- Evaluation, *see* Diagnosis
- Experimental fetal therapy, ethical issues in, 194-195
- Experimentation, treatment versus, 223-232
 - limits of definition, 224-225
 - truism about, 225-230
- Exploratory laparotomy for necrotizing enterocolitis in micropremies, anesthesia for, 397-399
- Extremely low birth weight infants, *see* Care of extremely low birth weight infants; Micropremies, anesthesia of
- Facilitation of infant's perceived goals, NIDCAP and, 436
- Familial hypocalciuric hypercalcemia (FHH), differential diagnosis of, 488-489
- Family members' interests, consideration of, in delivery room, 201-202, 204-205
- Fasting prior to general anesthesia for neonatal emergency surgery, 363
- Fatty liver of pregnancy, *see* Acute fatty liver of pregnancy
- Feasibility of neonatal pain measures, *see* Utility and feasibility of neonatal pain measures
- Female fetus, diagnosis of 11- β -hydroxylase CAH in, 454
- Fentanyl, 421, 422
 - maternal anesthesia with, neonatal effects of, 351, 352, 358
 - in micropremie anesthesia, 395, 396, 398, 399
 - for neonatal emergency surgery, 370-373, 375, 376
 - opioid tolerance and, 427, 431
- Fertility
 - 11- β -hydroxylase deficiency and 21-hydroxylase deficiency CAH effects on, 449
 - prolactinoma and, 459
- Fetal diagnosis, 190-194
 - ethical issues after, 191-194
 - ethical issues before, 190-191
 - of 11- β -hydroxylase deficiency CAH, 454
 - of 21-hydroxylase deficiency CAH, 450-451, 453
 - of syphilis, 326-327
 - of toxoplasmosis, 334-335
- Fetal effects of maternal general anesthesia, *see* General anesthesia, maternal, neonatal and fetal effects of
- Fetal exposure to opioids, neonatal opioid tolerance and, 427-428
- Fetal hydrops, and maternal parvovirus B19 infections, 312-313
- Fetal infections, *see* Perinatal infectious disease(s)
- Fetal monitoring, and maternal cirrhosis and portal hypertension, 159-160
- Fetal morbidity
 - with HELLP, 122
 - with HSV infection, 287
 - with ICP, 106-107
 - with parvovirus B19 infection and, 312-313
 - see also specific conditions*
- Fetal mortality
 - HELLP and, 122
 - HSV infection and, 287
 - ICP and, 106-107
 - liver hematoma and rupture and, 146
 - parvovirus B19 infections and, 312, 314
 - pheochromocytoma and, 477
 - see also specific conditions*
- Fetal outcome
 - with AFLP, 136
 - with CRS, 320
 - with measles, 322
 - with parvovirus B19 infections, 312-314
 - and postliver transplant pregnancy, 152
 - see also* Fetal morbidity; Fetal mortality and specific conditions
- Fetal therapy
 - experimental, ethical issues in, 194-195
 - of 21-hydroxylase deficiency CAH, 451-452
 - of parvovirus B19 infections, 314
 - of toxoplasmosis, 337
- Fetus
 - female, diagnosis of 11- β -hydroxylase CAH in, 454
 - physician's moral obligations to, 185-187
 - see also entries beginning with terms:* Congenital, Fetal, Prenatal
- FHH (familial hypocalciuric hypercalcemia), differential diagnosis of, 488-489
- Fifth disease (erythema infectiosum), parvovirus B19 and, 311
- Financial pressures on managed care of reproductive health, 234-235
- First-trimester liver diseases, 100
- FK 506 (tacrolimus) for pregnant liver transplant recipients, 151
- Fluid and metabolic requirements in general anesthesia for neonatal emergency surgery, 375-376
- Functional deficiencies of neonatal immune system, 3-5
 - of complement system, 5
 - of neutrophils, 3-4
- Functional response of neonatal T cells, 8
- Futility of care considerations
 - in delivery room, 202-205
 - see also* Futility of care considerations in NICUs
- Futility of care considerations in NICUs, 216-222
 - autonomy principle, increased parental role in decision making and, 217-218
 - Baby Doe regulations and, 218
 - the concept, 221-222
 - distributive justice, rationing of care and, 220-221
 - ethics committees function and, 218-219
 - providers' right to refuse treatment on basis of, 219-220

- GBS infections, *see* Group B streptococcus infections, maternal; Group B streptococcus infections, neonatal
- GBV (hepatitis B virus) infection in pregnancy, 115
- General anesthesia, *see* Emergency surgery, general anesthesia for neonatal; General anesthesia, maternal, neonatal and fetal effects of; Regional anesthesia, neonatal general anesthesia and
- General anesthesia, maternal, neonatal and fetal effects of, 354-359
- of induction agents, 354-356
 - of inhalational agents, 357-358
 - of NMBs, 356-357
 - of opioids, 358-359
 - regional anesthesia effects compared with, 359
- Genetic counseling, informed consent and, 190
- Genetics, *see* Reproductive genetics, ethics in
- Genital tract infections, upper, BV and, 245-247; *see also* Bacterial vaginosis
- German measles (rubella) in pregnancy, 318-321
- Gestational age
- and effectiveness of preventive IVIg, 52-54
 - see also* Preterm birth and delivery
- Glucocorticoids for endocrine disorders of pregnancy, 449-454, 464-466
- Glucose regulation in micropremies, anesthesia and, 393
- Glycopyrrolate, 363
- Granulocyte colony-stimulating factor test, early onset neonatal bacterial infection diagnosis with, 23
- Granulomatous diseases, as nonneoplastic liver masses in pregnancy, 174-175
- Group B streptococcus (GBS) infections, maternal, 267-276
- microbiology and immunology of, 267-268
 - neonatal and, 270-273; *see also* Group B streptococcus infections, neonatal
- Group B streptococcus (GBS) infections, neonatal, 33-49
- clinical manifestations of, and mortality with, 35-36
 - epidemiology of, 34-35
 - maternal and, 270-273
 - microbiology of, 33-34
 - prevention of, *see* Prevention of neonatal GBS infections
- Group review, prior, for experimental fetal therapy, 194
- Guidelines and recommendations
- managed care practice, taking into account medical necessity in reproductive health care, 235-236
 - for prevention of neonatal GBS infections, 42-46
 - for use of RSVIg, 92-93
- Halothane, 357, 369, 370, 394, 395
- HAV (hepatitis A virus) infection in pregnancy, 112, 277-278
- HBV (hepatitis B virus) infection in pregnancy, 112-115, 278-280
- HCC (hepatocellular carcinoma) in pregnancy, 163, 170-172
- HCV (hepatitis C virus) infection in pregnancy, 114-116, 281-282
- HDV (hepatitis D virus) infection in pregnancy, 114, 280-281
- HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome in pregnancy, 118-133
- AFLP and, 137-138
 - clinical presentation of, 118-119
 - differential diagnosis of, 119-121
 - morbidity with, 121-122
 - natural history of, 123
 - prognosis of, 122-123
 - subsequent pregnancy outcome, contraception, and prevention of, 128-130
 - therapy and management of, 123-128
- Helper function of T cells, 9
- Hematoma, *see* Liver hematoma and rupture in pregnancy
- Hemolysis, elevated liver enzymes, and low platelets syndrome, *see* HELLP syndrome in pregnancy
- Hemolytic uremic syndrome (HUS), clinical characteristics of, 120
- Hemorrhages
- intraventricular, risk of, in anesthesia of micropremies, 393-394
 - variceal, as complications of cirrhosis and portal hypertension in pregnancy, 161
- Hepatic cysts, as nonneoplastic liver masses in pregnancy, 175
- Hepatic failure, as complication of cirrhosis and portal hypertension in pregnancy, 161-162
- Hepaticolenticular degeneration (Wilson's disease), contraception for patients with, 180
- Hepatitis A virus (HAV) infection in pregnancy, 112, 277-278
- Hepatitis B virus (HBV) infection in pregnancy, 112-115, 278-280
- Hepatitis C virus (HCV) infection in pregnancy, 114-116, 281-282
- Hepatitis D virus (HDV) infection in pregnancy, 114, 280-281
- Hepatitis E virus (HEV) infection in pregnancy, 115, 282
- Hepatitis G virus (HGV) infection in pregnancy, 115, 281-282
- Hepatitis GB virus (GBV) infection in pregnancy, 115
- Hepatitis in pregnancy, 112-117, 277-283
- chronic active, therapy of, 115-116
 - contraception for, 179
 - GBV infection, 115
 - HAV infection, 112, 277-278
 - HBV infection, 112-115, 278-280
 - HCV infection, 114-116, 281-282
 - HDV infection, 114, 280-281
 - HEV infection, 115, 282
 - HGV infection, 115, 281-282
- Hepatocellular carcinoma (HCC) in pregnancy, 163, 170-172
- Hepatorenal syndrome, as complication of cirrhosis and portal hypertension in pregnancy, 162

- Herpes simplex virus (HSV) infections, neonatal, 64-71
 diagnosis of, 65-67
 morbidity and mortality with, 67-68, 287-288
 therapy of, 69-71, 289
- Herpes simplex virus (HSV) infections in pregnant women, 284-292
 clinical presentation of, 286-287
 diagnosis of, 285-286
 epidemiology of, 285-286
 prevention of, 289-290
 therapy of, 288-289
 virology of, 284-285
- HEV (hepatitis E virus) infection in pregnancy, 115, 282
- HGV (hepatitis G virus) infection in pregnancy, 115, 281-282
- History
 of BV, 242
 of parvovirus B19 infection, 309
 see also Natural history
- HIV infection, *see* HIV infection, neonatal; HIV infection in pregnant women
- HIV (human immunodeficiency virus) infection, neonatal, 79-84
 definitive diagnosis of, 79-82
 routine care of, 82-84
- HIV (human immunodeficiency virus) infection in pregnant women, 73-79, 293-308
 antiretroviral therapy of, 74-79, 84, 295, 300, 302-304
 counseling for, 296
 diagnosis of, 73-74, 295-296
 epidemiology of, 293-294
 HIV infection-pregnancy interactions, 296-302; *see also* Transmission of HIV infection
 routine care of, 73-74
 virology and pathogenesis of, 294-295
- Homeostasis, calcium, during pregnancy, 485-487;
 see also Parathyroid disorder(s) in pregnancy
- Horizontal transmission, *see* Transmission
- Hormone replacement therapy, 462-465
- HPT (hyperparathyroidism) in pregnancy, 487-490
- 3 β -HSD (3 β -hydroxysteroid dehydrogenase) deficiency congenital adrenal hyperplasia (CAH) in pregnancy, 454
- HSV infections, *see* Herpes simplex virus infections, neonatal; Herpes simplex virus infections in pregnant women
- Human immunodeficiency virus infection, *see* HIV infection, neonatal; HIV infection in pregnant women
- HUS (hemolytic uremic syndrome), clinical characteristics of, 120
- Hydrops, fetal, and maternal parvovirus B19 infections, 312-313
- 11- β -Hydroxylase deficiency congenital adrenal hyperplasia (CAH) in pregnancy, 453-454
- 21-Hydroxylase deficiency congenital adrenal hyperplasia (CAH) in pregnancy, 449-453
- 3 β -Hydroxysteroid dehydrogenase (3 β -HSD) deficiency congenital adrenal hyperplasia (CAH) in pregnancy, 454
- Hyperaldosteronism, primary, and hypertension in pregnancy, 474-475
- Hypercalcemia, hyperparathyroidism and, in pregnancy, 488-490
- Hypercortisolemia (Cushing's syndrome) in pregnancy, 479-482
- Hyperparathyroidism (HPT) in pregnancy, 487-490
- Hyperplasia, *see* Congenital adrenal hyperplasia in pregnancy
- Hyperprolactinemia, prolactinoma and, 458-463
- Hypersplenism, as complication of cirrhosis and portal hypertension in pregnancy, 162
- Hypertension, *see* Cirrhosis and portal hypertension in pregnancy; Hypertension in pregnancy, endocrine cause(s) of
- Hypertension in pregnancy, endocrine cause(s) of, 471-484
 Cushing's syndrome as, 479-482
 pheochromocytoma as, 476-479
 renin-angiotensin-aldosterone system-mediated, 471-475
- Hypocalciuric hypercalcemia, familial, differential diagnosis of, 488-489
- Hypoparathyroidism in pregnancy, 490-491
- Hypophysitis, lymphocytic, in pregnancy, 465
- Hypopituitarism in pregnancy, 464-465
- Hypothalamic-pituitary-adrenal axis, changes in, in normal pregnancy, 447-448
- IAI, *see* Intraamniotic infection
- IBCS (Infant Body Coding System), neonatal pain assessment with, 405, 406
- Ibuprofen, 421
- ICP, *see* Intrahepatic cholestasis of pregnancy
- Ig, *see* Immunoglobulin(s)
- IL-6 (interleukin-6) test, early onset neonatal bacterial infection diagnosis with, 22-23
- Immunization
 against GBS infection to prevent neonatal infection, 36-37, 270, 273
 against HAV infection, 278
 against HBV infection, 279-280
 against rubella, 319-320
 against rubeola, 322
 against VZV infection, 345
 see also Immunoglobulin therapy
- Immunodeficiency
 parvovirus B19 infection and, 311-312
 see also HIV infection, neonatal; HIV infection in pregnant women
- Immunoglobulin(s) (Ig)
 neonatal, 10-11
 therapy with, *see* Immunoglobulin therapy
- Immunoglobulin (Ig), RSV, for RSV infection, 88-94
 cost/benefit analysis of, 93-94
 in RSV prevention, 88-90
 in RSV therapy, 90-93
- Immunoglobulin (Ig) therapy
 and HCV infection, 281
 for neonates born to HIV-infected mothers, 281
 for varicella, 343
 see also Immunoglobulin, RSV, for RSV infection;

- Intravenous immunoglobulin therapy for neonatal sepsis
- Immunology, *see* Neonatal immunology
- Immunosuppressants during postliver transplant pregnancy, 150-151
- Incidence
 - of BV, 242
 - of cirrhosis and portal hypertension in pregnancy, 157
 - of neonatal GBS infections, 34-35
 - of nosocomial infections in NICUs, 26, 27
 - of PPT, 497-498
 - see also* Epidemiology and specific conditions
- Indications
 - for EMLA cream in neonates, 386
 - for prenatal diagnosis, 190-191
 - for regional nerve blocks in neonates, 387
 - for RVSIg, 94
 - see also* specific conditions
- Indicators of pain in neonates, 413-414
- Indirect neonatal effects of maternal regional anesthesia, 351-353
- Indomethacin, 421
- Induction agents for maternal general anesthesia, neonatal and fetal effects of, 354-356
- Infant(s)
 - best interest of, as ethical consideration in delivery room, 201, 204-205
 - of HIV-infected pregnant women having received antiretroviral therapy, monitoring, 78-79
 - see also* Newborn and entries beginning with terms: Neonatal, Perinatal
- Infant Body Coding System (IBCS), neonatal pain assessment with, 405, 406
- Infant development, synactive theory of, NIDCAP model and, 435-437
- Infant Pain Evaluation Criteria (IPEC), 408, 411
- Infections
 - as nonneoplastic liver masses in pregnancy, 173-174
 - see also* Perinatal infectious disease(s)
- Inflammatory conditions, neonatal, analgesia of, 422
- Informed consent
 - for experimental fetal therapy, 195
 - genetic counseling and, 190
 - in managed care of reproductive health, 236-237
 - research stage of prenatal diagnosis procedure, and, 191
- Inguinal hernia repair in micropremies, anesthesia for, 396-397
- Inhalational anesthetics
 - in maternal general anesthesia, neonatal and fetal effects of, 357-358
 - see also* Inhalational anesthetics, pharmacology of and specific inhalational anesthetics
- Inhalational anesthetics, pharmacology of
 - in micropremies, 394-395
 - in neonatal emergency surgery, 368-370
- Intensive care
 - for all extremely low birth weight infants, 210-212
 - see also* Analgesia, neonatal; Futility of care considerations in NICUs; Low birth weight infants; Nosocomial infections in NICUs
- Interest(s)
 - best infant, as ethical consideration in delivery room, 201, 204-205
 - business, in managed care of reproductive health, professional obligations and, 234
 - family members', as ethical consideration in delivery room, 201-202, 204-205
- Interleukin-6 (IL-6) test, early onset neonatal bacterial infection diagnosis with, 22-23
- Intraamniotic infection (IAI), 251-259
 - diagnosis of, 253-255
 - maternal outcome with, 256-257
 - microbiology of, 252-253
 - neonatal outcome with, 255-256
 - prevention of, 253
 - risk factors for, 251-252
 - therapy of, 255
- Intrahepatic cholestasis of pregnancy (ICP), 104-111
 - clinical course of, 105-106
 - contraception for patients with, 180
 - epidemiology of, 104
 - fetal morbidity and mortality with, 106-107
 - management of, 107-109
 - maternal outcome with, 106
 - pathogenesis of, 104-105
- Intrapartum prophylaxis of GBS infections, 39-46, 271-273
- Intravascular catheters, and nosocomial infections in NICUs, 28-29
- Intravenous anesthetics, pharmacology of
 - in micropremies, 395-396
 - in neonatal emergency surgery, 370-371
- Intravenous immunoglobulin (IVIg) therapy for neonatal sepsis, 50-63
 - evaluation of, 57-61
 - for GBS infections, 271
 - preventive role of, *see* Prevention of neonatal sepsis with IVIg
- Intraventricular hemorrhage (IVH), risk of, in anesthesia of micropremies, 393-394
- In utero conditions and interventions, *see* Fetus
- IPEC (Infant Pain Evaluation Criteria), 408, 411
- Isoflurane, 357, 369, 394-396, 398
- IVH (intraventricular hemorrhage), risk of, in anesthesia of micropremies, 393-394
- IVIg, *see* Intravenous immunoglobulin therapy for neonatal sepsis
- Justice
 - principle of, in managed care reproductive health, 238-239
 - rationing of care and distributive, futility of care considerations in NICUs and, 220-221
- Ketamine, 354, 421
 - in micropremie anesthesia, 395, 396, 398, 399
 - in neonatal regional anesthesia, 380
 - for neonatal surgical emergencies, 371, 376
- Ketoconazole, 481
- Ketorolac tromethamine, 397, 421
- Labor and delivery

- regional anesthesia effects on maternal thermoregulation during, 353
- see also* Obstetric management; Preterm birth and delivery
- Laboratory evaluation
 - of HIV-infected pregnant women, 73-74
 - of parvovirus B19 infection, 309-310
 - see also* Diagnosis; Laboratory evaluation of early onset neonatal bacterial infections
- Laboratory evaluation of early onset neonatal bacterial infections, 17-23
 - with blood cell count, 20-22
 - with blood culture, 17-19
 - with CRP test, 22
 - with IL-6 test, 22-23
 - with lumbar puncture, 19-21
 - with neutrophil respiratory bursts, granulocyte colony-stimulating factor, and procalcitonin tests, 23
 - with urine culture and latex agglutination, 22
- Laparotomy, exploratory, for necrotizing enterocolitis in micropremies, anesthesia for, 397-399
- Late congenital syphilis, 325, 326
- Late nosocomial infections, neonatal, IVIg in prevention of, 56
- Late-onset nosocomial infections, neonatal, IVIg in prevention of, 56
- Latex agglutination, early onset neonatal bacterial infection diagnosis with, 22
- Legal aspects of intensive care withdrawal, 214
- Leukocytes, *see* B cells, neonatal; Neutrophil(s); T cell(s), neonatal
- Lidocaine, 376, 382, 384, 385, 386
- LIDS (Liverpool Infant Distress Score), neonatal pain assessment with, 405-407
- Life-sustaining care of extremely low birth weight infants, withholding versus withdrawing, 213-214
- Ligation, PDA, in micropremies, anesthesia for, 399
- Limiting care of extremely low birth weight infants based on survival probability, 210-211
- Liver disease in pregnancy
 - introduction to, 97
 - see also* Acute fatty liver of pregnancy; Cirrhosis and portal hypertension in pregnancy; Contraception for liver disease patient; HELLP syndrome in pregnancy; Hepatitis in pregnancy; Intrahepatic cholestasis of pregnancy; Liver function in pregnancy, evaluation of abnormal; Liver hematoma and rupture in pregnancy; Liver masses in pregnancy; Liver transplantation, pregnancy and
- Liver function in pregnancy, evaluation of
 - abnormal, 98-103
 - in normal pregnancy, 98
 - patterns of liver function abnormalities and, 98-99
 - in pregnancy-associated liver diseases, 99-100
 - signs and symptoms of liver diseases and, 100-101
 - tests for, 101-102
- Liver hematoma and rupture in pregnancy, 141-148
 - clinical presentation of, 142-143
 - diagnosis of, 142-144
 - epidemiology of, 141
 - pathophysiology of, 141-142
 - prognosis of, 146
 - therapy of, 144-146
- Liver masses in pregnancy, 166-177
 - benign neoplasms as, 169-171
 - clinical presentation of, 167
 - diagnosis and evaluation of, 167-169
 - nonneoplastic, 173-175
 - primary malignant, 163, 170-172
 - secondary malignant neoplasms as, 172-173
- Liver transplantation, pregnancy and pregnancy after, *see* Postliver transplantation pregnancy
 - during pregnancy and puerperium and, 153-154
- Liverpool Infant Distress Score (LIDS), neonatal pain assessment with, 405-407
- Local anesthetics
 - pharmacology of, in neonates, 382
 - see also* specific local anesthetics
- Lorazepam, 431
- Low birth weight infants
 - and nosocomial infections in NICUs, 26, 28
 - see also* Care of extremely low birth weight infants; Micropremies, anesthesia of
- Lumbar puncture, early onset neonatal bacterial infection diagnosis with, 19-21
- Lymphocytic hypophysitis in pregnancy, 465
- Malignant liver neoplasms in pregnancy, 171-173
 - primary, 163, 170-172
 - secondary, 172-173
- Malnutrition, as complication of cirrhosis and portal hypertension in pregnancy, 163-164
- Management, *see* Therapy and management
- Maternal anesthesia, neonatal effects of, 350-362
 - of general anesthesia, *see* General anesthesia, maternal, neonatal and fetal effects of
 - and placental drug transfer, 350-351
 - of regional anesthesia, 351-353, 359
- Maternal complications
 - of cirrhosis and portal hypertension, 161-164
 - of fetal CAH therapy, 453
 - of HELLP, 121-122
 - of parvovirus B19 infections, 312
 - see also* Maternal morbidity and specific conditions
- Maternal immunization, *see* Immunization
- Maternal infections, *see* Perinatal infectious disease(s)
- Maternal monitoring for cirrhosis and portal hypertension, 159-160
- Maternal morbidity
 - with HELLP, 121-122
 - with liver hematoma and rupture, 146
 - see also* specific conditions
- Maternal mortality
 - with HELLP, 121
 - with pheochromocytoma, 477
- Maternal outcome
 - with AFLP, 136
 - with IAI, 256-257
 - with ICP, 106

- with measles, 322
- with postliver transplantation pregnancy, 151-152
- with subsequent pregnancy in HELLP patients, 128-130
- see also* Maternal complications; Maternal morbidity; Maternal mortality
- Maternal therapy, *see* Therapy and management, maternal
- Maximally Discriminative Facial Coding System (MAX), neonatal pain assessment with, 404, 405
- Meaningfulness of infant's behavior, NIDCAP and, 436
- Measles (rubeola) in pregnancy, 321-322
- Measures of neonatal pain, 402-416
 - discussion on, 410, 412-413
 - multidimensional, 407-413
 - pain indicators in, 413-414
 - psychometric properties of, 403-404; *see also* Reliability of neonatal pain measures; Utility and feasibility of neonatal pain measures; Validity of neonatal pain measures
 - unidimensional, 404-407
- Medical innovations and research, *see* Research
- Medical necessity in managed care of reproductive health, practice guidelines taking into account, 235-236
- Meperidine, 358, 359, 421
- Metabolic and fluid requirements in general anesthesia for neonatal emergency surgery, 375-376
- Methadone, 421, 431
- Metyrapone, 481
- Microbiology
 - of BV, 243
 - of CMV infection, 260
 - of early onset neonatal bacterial infections, 15-16
 - of GBS infections, 33-34
 - of IAI, 252-253
- Microorganisms
 - associated with neonatal nosocomial infections, 28, 29
 - birth canal, early onset neonatal bacterial infections associated with, 16
 - killing of, by neutrophils, 3
 - see also* Microbiology
- Micropremies, anesthesia of, 390-401
 - in exploratory laparotomy for necrotizing enterocolitis, 397-399
 - for inguinal hernia repair, 396-397
 - for PDA ligation, 399
 - pharmacology of anesthetic agents used with, 394-396
 - risks involved in, *see* Risk(s) of anesthesia in micropremies
- Midazolam, 371, 396, 419, 421
- Mills Infant/Toddler Pain Index (MITPI) of neonatal pain, 405, 407
- Mineralocorticoids for CAH, 450
- Mivacurium, 356, 375
- Molecular basis of diversity in neonatal acquired immunity, 5-6
- Monitoring
 - fetal and maternal, cirrhosis and portal hypertension and, 159-160
 - general anesthesia, for neonatal emergency surgery, 363-365
 - of infants of HIV-infected mothers on antiretroviral therapy, 78-79
 - post-spinal neonatal anesthesia, 383
- Monoclonal antibodies, RVS, in prevention of RSV infection, 90-92
- Moral obligations, *see* Physicians, moral obligations of
- Morbidity, *see* Fetal morbidity; Maternal morbidity; Neonatal morbidity and specific conditions
- Morphine, 358
 - for micropremies, 399
 - for neonatal analgesia, 419, 421-422
 - for neonatal emergency surgery, 371-372, 377
 - opioid tolerance and, 427, 431
- Mortality, *see* Fetal mortality; Maternal mortality; Mortality, neonatal
- Mortality, neonatal
 - with GBS infections, 35-36
 - with HSV infection, 67-68, 288
 - with maternal cirrhosis and portal hypertension, 164
 - with maternal HELLP, 122
- Multidimensional neonatal pain measures, 407-413
- Multifetal pregnancy, abortion of, following prenatal diagnosis, 192-194
- Muscle relaxants, *see* Neuromuscular blocker(s)
- Mycophenolate mofetil in pregnant liver transplant recipients, 151
- Nalbuphine, 358
- Naloxone, 358, 422
- Natural history
 - of HELLP, 123
 - of HIV infection in pregnant and nonpregnant women, 298-299
- Necrotizing enterocolitis, exploratory laparotomy for, in micropremies, anesthesia for, 397-399
- Neonatal anesthesia
 - introduction to, 347-349
 - see also* Analgesia, neonatal; Emergency surgery, anesthesia for neonatal; Maternal anesthesia, neonatal effects of; Micropremies, anesthesia of; Regional anesthesia and analgesia, neonatal and entries beginning with terms: General anesthesia
- Neonatal Facial Coding System (NFCS), neonatal pain assessment with, 404-406
- Neonatal immunology, 2-14
 - acquired immunity and, *see* Acquired immunity, neonatal
 - B cells and Igs in, 10-11
 - complement system in, 4-5
 - neutrophils in, 2-4
- Neonatal Infant Pain Scale (NIPS), 407-408, 411
- Neonatal infections, *see* Perinatal infectious disease(s)
- Neonatal intensive care units, *see* Intensive care
- Neonatal morbidity
 - with HELLP, 121-122

- with HSV infection, 67-68, 287-288
see also specific conditions
- Neonatal neurobehavioral responses to maternal regional anesthesia, 353
- Neonatal outcome
extremely low birth weight and, care decision and, 208
with IAI, 255-256
measles and, 322
and postliver transplant pregnancy, 152
with toxoplasmosis, 337
see also Mortality, neonatal; Neonatal morbidity and specific conditions
- Neonatal Pain Assessment Scale (NPAS), 409, 411
- Neoplasms in pregnancy
benign liver, 169-171
see also Malignant liver neoplasms in pregnancy
- Neostigmine, 375
- Neural axis anesthesia, neonatal, 382-384
- Neurobehavioral responses, neonatal, to maternal regional anesthesia, 353
- Neurobehaviorally supportive relationship-based care, NIDCAP and, 438
- Neuromuscular blocker(s) (NMB)
in maternal general anesthesia, neonatal and fetal effects of, 356-357
in neonatal anesthesia for emergency surgery, pharmacology of, 373-375
see also specific neuromuscular blockers
- Neuromuscular blocker (NMB) antagonists, 375
- Neutrophil(s) (polymorphonuclear leukocytes), neonatal, 2-4
- Neutrophil respiratory burst test, early onset neonatal bacterial infection diagnosis with, 23
- New diabetes insipidus, development of, in pregnancy, 467-468
- Newborn
physician's moral obligations to, 187
varicella of, 343
see also Infant and entries beginning with terms:
Neonatal, Perinatal
- Newborn Individualized Developmental Care and Assessment Program (NIDCAP), 435-437
- NFCS (Neonatal Facial Coding System), neonatal pain assessment with, 404-406
- NICUs (neonatal intensive care units), *see Intensive care*
- NIDCAP (Newborn Individualized Developmental Care and Assessment Program) 435-437
- NIPS (Neonatal Infant Pain Scale), 407-408, 411
- Nitroglycerin, 386
- Nitroprusside, 386
- Nitrous oxide (N_2O), 354, 356-358, 370, 394-397
- NMB, *see Neuromuscular blocker(s)*
- N_2O (nitrous oxide), 357, 358, 370, 394-397
- Nociception, defined, 417
- Non-A, non-B hepatitis, *see Hepatitis C virus infection; Hepatitis G virus infection; Hepatitis GB virus infection*
- Nonfunctioning pituitary tumors in pregnancy, 464
- Nonneoplastic liver masses in pregnancy, 173-175
- Nonnoxious stimuli stimulation, neonatal pain management with, 439
- Non-nutritive sucking in neonatal pain management, 439
- Nonpharmacological methods
of analgesia and sedation in NICUs, 420, 421
of reducing risk of HIV transmission, 79
- Nonpregnant women, natural history of HIV infection in, 298-299
- Nonspecific vaginitis, *see Bacterial vaginosis*
- Normal pregnancy
abnormal liver function evaluation in, 98
calcium homeostasis during, 485-487; *see also Parathyroid disorder(s) in pregnancy*
catecholamines in, 476
CRH in, 479
hypothalamic-pituitary-adrenal axis in, 447-448
renin-angiotensin-aldosterone system in, 472-473
- Normal vaginal flora, 242-243
- Nosocomial infections in NICUs, 25-32
epidemiology of, 25-26
prevention of, *see Prevention of neonatal nosocomial infections*
rates of, 26, 27
risk factors for, 26-30
- Noxious stimuli reduction, neonatal pain management with, 437
- NPAS (Neonatal Pain Assessment Scale), 409, 411
- Nugent scoring system for BV diagnosis, 244
- Nursing (breast feeding)
HIV transmission through, 82, 301-302
and osteoporosis, 493-494
with prolactinoma, 462
- Obligations, *see Physicians, moral obligations of; Professional obligations in managed care of reproductive health*
- Obstetric management
of AFLP patients, 138
of cirrhosis and portal hypertension patients, 160
of ICP patients, 107
of liver transplant recipients, 152-153
see also Delivery room, ethical consideration(s) in; Preterm birth and delivery
- Opioid(s)
in maternal general anesthesia, neonatal and fetal effects of, 358-359
mechanisms of action of, 426-427
see also Opioid(s) in neonatal anesthesia and specific opioids
- Opioid(s) in neonatal anesthesia
for emergency surgery, pharmacology of, 371-373
see also Opioid tolerance in neonates
- Opioid tolerance in neonates, 425-433
adverse effects of opioids and, 427
defined, 425
factors affecting development of, 430
in utero opioid exposure and, 427-428
mechanisms of opioid action and, 426-427
withdrawal and, *see Withdrawal, neonatal opioid*
- Osteoporosis in pregnancy, 492-494
- Outcome, *see Fetal outcome; Maternal outcome; Neonatal outcome; Patient survival; Pregnancy outcome; Prognosis and specific conditions*

- P. carinii* (*Pneumocystis carinii* pneumonia (PCP), prevention of, in HIV-infected neonates, 83-84
- P450_{c11} deficiency (11 β -hydroxylase deficiency) congenital adrenal hyperplasia (CAH) in pregnancy, 453-454
- P450_{c21} deficiency (21-hydroxylase deficiency) congenital adrenal hyperplasia (CAH) in pregnancy, 449-453
- Pain, 417-420
 - ability of pain assessment tools to detect changes in level of, 414; *see also* Measures of neonatal pain
 - acute, 418-419
 - chronic, *see* Chronic pain
 - defined, 417
 - physiological effects of, 417-418
 - procedural, 419-420
 - sensitivity to, *see* Sensitivity to pain, neonatal
 - see also* Analgesia, neonatal
- Pain Assessment Tool (PAT), 410, 412
- Pancuronium, 373, 398, 399, 419
- Parasitology of toxoplasmosis, 332-333
- Parathyroid disorder(s) in pregnancy, 485-496
 - calcium homeostasis during pregnancy and, 485-487
 - HPT as, 487-490
 - hypoparathyroidism as, 490-491
 - osteoporosis as, 492-494
 - pseudohypoparathyroidism as, 492
- Parathyroid hormone-related protein (PTHrp)-associated hypercalcemia, differential diagnosis of, 489-490
- Paregoric, 431
- Parental role in decision making
 - on care of extremely low birth weight infants, 212-213
 - futility of care considerations in NICUs and, 217-218
- Parvovirus B19 infections in pregnancy, 309-317
 - congenital birth defects due to, 313
 - EI and, 311
 - fetal outcome with, 312-314
 - history and virology of, 309
 - in immunodeficient patients or patients with chronic anemia, 311-312
 - laboratory evaluation of, 309-310
 - pregnancy outcome with, 313-314
 - therapy and management of, 314-316
 - transmission of, 310
- PAT (Pain Assessment Tool), 410, 412
- Patent ductus arteriosus (PDA) ligation in micropremies, anesthesia for, 399
- Pathology, pathogenesis, and pathophysiology of AFLP, 134-135
 - of congenital adrenal hyperplasia in pregnancy, 448-449
 - of early onset neonatal bacterial infections, 15-16
 - of HIV infection, 294-295
 - of ICP, 104-105
 - of liver hematoma and rupture in pregnancy, 141-142
 - of PPT, 498-499
 - of syphilis, 323-324
 - of VZV infection, 339-340
 - see also* specific conditions
- Patient advocacy in managed care of reproductive health, 237-238
- Patient survival, probability of extremely low birth weight, limiting care based on, 210-211
- PCP (*Pneumocystis carinii*) pneumonia, prevention of, in HIV-infected neonates, 83-84
- PCR, *see* Polymerase chain reaction diagnosis
- PDA (patent ductus arteriosus) ligation in micropremies, anesthesia for, 399
- Penile nerve block, dorsal, for neonatal circumcision, 385
- Perceived goals of infant, NIDCAP and facilitation of, 436
- Percutaneous transluminal angioplasty of renovascular hypertension, 474
- Pergolide, 459
- Perinatal infectious disease(s)
 - introduction to, 1, 241
 - rubella as, 318-321
 - rubeola as, 321-322
 - see also* Bacterial vaginosis; Cytomegalovirus infection; Early onset neonatal bacterial infections; Group B streptococcus infections, maternal; Group B streptococcus infections, neonatal; Hepatitis in pregnancy; Herpes simplex virus infections, neonatal; Herpes simplex virus infections in pregnant women; HIV infection, neonatal; HIV infection in pregnant women; Intraamniotic infection; Neonatal immunology; Parvovirus B19 infections in pregnancy; Respiratory syncytial virus infection, neonatal; Syphilis in pregnancy; Toxoplasmosis; Varicella
- Persistent pain, *see* Chronic pain
- Phagocytosis by neutrophils, 3
- Pharmacology of anesthetics used with neonates, 368-375
 - of inhalational agents, 368-370
 - of intravenous anesthetics, *see* Intravenous anesthetics, pharmacology of
 - of local anesthetics, 382
 - with micropremies, 394-396
 - of NMBs, 373-375
 - of opioids, 371-373
 - of relaxant antagonists, 375
- Phenobarbital, 386, 431-432
- Phenoxybenzamine, 478
- Phentolamine mesylate, 478
- Phenylephrine, 353
- Phenytoin, 386
- Pheochromocytoma in pregnancy, 476-479
- Phosphate supplementation, 490
- Physicians
 - right of, to refuse treatment, futility of care considerations in NICUs and, 219-220
 - see also* Physicians, moral obligations of; Professional obligations in managed care of reproductive health
- Physicians, moral obligations of, 184-188
 - to fetus, 185-187

- to newborn, 187
- to pregnant woman, 184-185
- Physiological dependence, defined, 425
- Physiological effects of pain, 417-418
- Physiology
 - of catecholamines, 476
 - of CRH, 479
 - of renin-angiotensin-aldosterone system, 471-472
- PIPP (Premature Infant Pain Profile), 409, 411
- Pituitary disease(s) and tumor(s) in pregnancy, 454-470
 - acromegaly as, 463-464
 - clinically nonfunctioning tumors and TSH-secreting tumors as, 464
 - diabetes insipidus as, 467-468
 - hypopituitarism as, 464-465
 - lymphocytic hypophysitis as, 465
 - prolactinoma as, 458-463
 - Sheehan's syndrome as, 465-466
- Placental drug transfer, maternal anesthesia and, 350-351
- Placental transport of Igs, 11
- Plasma adrenocorticotropin hormone (ACTH; corticotropin), normal ranges of, in pregnancy, 447
- Plasma-free cortisol, normal ranges of, in pregnancy, 447
- Pneumocystis carinii* (*P. carinii*) pneumonia (PCP), prevention of, in HIV-infected neonates, 83-84
- Pneumonia, *P. carinii*, prevention of, in HIV-infected neonates, 83-84
- Polymerase chain reaction (PCR) diagnosis
 - of HCV infection, 114
 - of HEV infection, 115
 - of HGV infection, 282
 - of HSV infection, 286
 - of neonatal HIV infection, 79-81
 - of neonatal HSV infection, 65-67
 - of parvovirus B19 infections, 310
 - of toxoplasmosis, 335
- Polymorphonuclear leukocytes (neutrophils), neonatal, 2-4
- Portal hypertension, *see* Cirrhosis and portal hypertension in pregnancy
- Positioning and containing of infant in neonatal pain management, 439
- Postliver transplantation pregnancy, 149-155 and contraception for transplant recipient, 153, 181
 - fetal and neonatal outcome with, 152
 - immunosuppressants and, 150-151
 - maternal outcome with, 151-152
 - obstetric management of, 152-153
 - preconception counseling for, 149-150
- Postnatal antibiotic prophylaxis of neonatal GBS infections, 37-38
- Postpartum hypercalcemia, differential diagnosis of, 489
- Postpartum management
 - of cirrhosis and portal hypertension patients, 160-161
 - of prolactinoma patients, 462
- Postpartum thyroiditis (PPT), 497-502
 - clinical features of, 499-500
 - incidence of, 497-498
 - pathogenesis of, 498-499
 - screening for, 500-501
 - therapy of, 501
- PPT, *see* Postpartum thyroiditis
- Preconception counseling
 - of cirrhosis and portal hypertension patients, 158-159
 - of liver transplant recipients, 149-150
 - of prolactinoma patients, 462
- Preeclampsia, AFLP and, 137-138
- Pregnancy
 - and physician's moral obligations to pregnant patient, 184-185
 - see also* Normal pregnancy; Pregnancy effects; Pregnancy outcome and specific conditions; for example: Liver disease in pregnancy; Perinatal infectious disease(s)
- Pregnancy effects
 - on acromegaly, 463
 - on hypothalamic-pituitary-adrenal axis, 447-448
 - on prolactinoma, 460-461
- Pregnancy outcome
 - with Cushing's syndrome, 480
 - effects of acromegaly and its treatment on, 463-464
 - effects of hyperprolactinemia and its treatment on, 461-462
 - with 11- β -hydroxylase deficiency CAH, 453-454
 - with 21-hydroxylase deficiency CAH, 449, 450
 - with pheochromocytoma, 477-479
 - with primary hyperaldosteronism, 475
 - with renovascular hypertension, 473
 - see also* specific conditions and outcomes; for example: Spontaneous abortion
- Premature infant(s)
 - EMLA cream use in, 387
 - sensitivity to pain in, 418; *see also* Measures of neonatal pain
 - see also* Analgesia and sedation in NICUs; Environmental and behavioral pain interventions in NICUs; Futility of care considerations in NICUs; Low birth weight infants; Preterm birth and delivery
- Premature Infant Pain Profile (PIPP), 409, 411
- Premedication in general anesthesia for neonatal emergency surgery, 363
- Prenatal screening for toxoplasmosis, 337
- Preterm birth and delivery
 - with cirrhosis and portal hypertension, 164
 - GBS infection and, 269
 - IAI and, 252
 - with LT, 152
 - measles and, 322
 - syphilis and, 324-325
 - see also* Preterm birth and delivery, BV and
- Preterm birth and delivery, BV and, 244-248
 - impact of BV therapy on, 247-248
 - upper genital tract infection and, 245-247
- Prevention
 - of CMV infection, 264-265

- of HELLP, 128-130
- of HSV infection, 289-290
- of IAI, 253
- of rubella, 319-320
- of rubeola, 322
- of toxoplasmosis, 335-336
- see also* Immunoglobulin therapy; Immunization; Prevention of neonatal infections
- Prevention of neonatal GBS infections, 36-46
 - with antibiotics, *see* Antibiotics, prophylaxis of neonatal GBS infections with
 - guidelines for, 42-46
 - with immunization, 36-37, 270, 273
 - intrapartum, 39-44, 271-273
 - with IVIg, 271
 - with vaginal antisepsis, 37
- Prevention of neonatal infections
 - of HAV infection, 278
 - of HBV infection, 279-280
 - of *P. carinii* pneumonia in HIV-infected neonates, 83-84
 - of RSV infection with antibodies, 88, 90-92; *see also* Immunoglobulin, RSV, for RSV infection
 - see also* Prevention of neonatal GBS infections; Prevention of neonatal nosocomial infections; Prevention of neonatal sepsis with IVIg
- Prevention of neonatal nosocomial infections
 - of late and late-onset infections with IVIg, 56
 - in NICUs, 30-31
- Prevention of neonatal sepsis with IVIg, 50-56
 - effectiveness of, 52-54
 - of late and late-onset nosocomial infections, 56
- Prilocaine, 386
- Primary biliary cirrhosis, contraception for patients with, 180
- Primary hyperaldosteronism, and hypertension in pregnancy, 474-475
- Primary malignant liver neoplasm, 163, 170-172
- Prior group review for experimental fetal therapy, 194
- Procalcitonin test, early onset neonatal bacterial infection diagnosis with, 23
- Procedures
 - in NICUs, pain due to, 419-420
 - strategies to reduce neonatal pain responses to procedural technique, 440-441
 - see also* specific procedures
- Professional obligations in managed care of reproductive health
 - broader, to groups of patients, 238-239
 - business interests and, 234
 - see also* Physicians, moral obligations of
- Prognosis
 - of HELLP, 122-123
 - of liver hematoma and rupture in pregnancy, 146
 - of rubella, 319
 - of rubeola, 321-322
 - of toxoplasmosis, 337
 - see also* Outcome and specific conditions
- Prolactinoma in pregnancy, 458-463
- Prophylaxis, *see* Prevention
- Propofol, 354-356, 371, 380, 395-396
- Protein, PTH-related, hypercalcemia associated with, 489-490
- Proven fetal therapy, refusal of, 195
- Providers of care, *see* Physicians
- Provisional intensive care for all extremely low birth weight infants, 211-212
- Pseudohypoparathyroidism in pregnancy, 492
- Psychometric properties of neonatal pain measures, 403-404; *see also* Reliability of neonatal pain measures; Utility and feasibility of neonatal pain measures; Validity of neonatal pain measures
- PTHrp (parathyroid hormone-related protein)-associated hypercalcemia, differential diagnosis of, 489-490
- Puerperium, liver transplantation during, 153-154
- Puncture, lumbar, early onset neonatal bacterial infection diagnosis with, 19-21
- Purpura, thrombotic thrombocytopenia, clinical characteristics of, 120
- Quality of life (QOL) consideration in delivery room, 200-201, 204-205
- Rationing of care, distributive justice and, and utility of care considerations in NICUs, 220-221
- Refusal, treatment
 - of proven fetal therapy, 195
 - providers' right to refuse treatment in NICUs on basis of utility of care, 219-220
- Regional anesthesia
 - maternal, neonatal effects of, 351-353, 359
 - see also* Regional anesthesia and analgesia, neonatal
- Regional anesthesia and analgesia, neonatal, 380-389
 - for circumcision, 384-387
 - for emergency surgery, 376-377
 - neural axis anesthesia as, 382-384
 - pharmacology of local anesthetics and, 382
 - side effects and complications of, 381-382
 - see also* Regional anesthesia and analgesia, neonatal general anesthesia and
- Regional anesthesia and analgesia, neonatal general anesthesia and
 - as adjunct to general anesthesia, 387
 - compared, 380-381
- Relationship-based caregiving based on NIDCAP model, 436
- Reliability of neonatal pain measures, 403
 - multidimensional measures, 411, 412
 - unidimensional measures, 405
- Remifentanyl, 373
- Renin-angiotensin-aldosterone system-mediated hypertension in pregnancy, 471-475
- Renovascular hypertension in pregnancy, 473-474
- Reproductive genetics, ethics in, 189-197
 - before experimental fetal therapy, 194-195
 - after prenatal diagnosis, 191-194
 - before prenatal diagnosis, 190-191
- Reproductive health, managed care of, 233-240
 - confidentiality in, 237

- financial pressures and, 234-235
justice principle in, 238-239
need for disclosure and informed consent in, 236-237
patient advocacy in, 237-238
practice guidelines taking into account medical necessity in, 235-236
professional obligations and, *see* Professional obligations in managed care of reproductive health
- Research
 research stage of prenatal diagnosis procedure, informed consent for, 191
 see also Experimental fetal therapy;
 Experimentation, treatment versus
- Resistance to antibiotics, nosocomial infections in NICUs and, 29-30
- Respiratory control of micropremies, anesthesia and, 391-392
- Respiratory mechanics, and anesthesia of micropremies, 390-391
- Respiratory responses to neonatal spinal anesthesia, 383
- Respiratory syncytial virus (RSV) infection, neonatal, 87-95
 in high-risk infants, epidemiology of, 87-88
 prevention of, with antibodies, 88, 90-92; *see also* Immunoglobulin, RSV, for RSV infection
- Retinopathy of prematurity (ROP), risk of, in anesthesia of micropremies, 393
- Retrovir (zidovudine) for HIV infection, 75-79, 84, 295, 300, 302-304
- Right of physicians to refuse treatment in NICUs on basis of futility of care, 219-220
- Ringer's solution, 352, 397
- Risk(s) of anesthesia in micropremies, 390-394
 to cardiovascular system, 392-393
 IVH as, 393-394
 respiratory control and, 391-392
 respiratory mechanics and, 390-391
 ROP as, 393
 thermoregulation, glucose regulation and, 393
- Risk(s) and risk factors
 of HIV transmission, *see* Transmission of HIV infection, reducing risk of
 for IAI, 251-252
 infants at high, for RSV infection, 87-88
 for neonatal GBS infections, 34-35
 for nosocomial infections in NICUs, 26-30
 see also Risk(s) of anesthesia in micropremies
- Rocuronium, 356, 374, 375
- ROP (retinopathy of prematurity), risk of, in anesthesia of micropremies, 393
- Ropivacaine, 351
- Routine care
 of HIV-infected neonates, 82-84
 of HIV-infected pregnant women, 73-74
- RSV infection, *see* Respiratory syncytial virus infection, neonatal
- Rubella (German measles) in pregnancy, 318-321
- Rubeola (measles) in pregnancy, 321-322
- Ruptured liver, *see* Liver hematoma and rupture in pregnancy
- S. agalactiae* (*Streptococcus agalactiae*), *see* Group B streptococcus infections, maternal; Group B streptococcus infections, neonatal
- Safety of RSVIg and monoclonal RSV antibodies, 91-92
- Screening
 for CMV infection, 264-265
 for GBS infections, 272, 273
 for PPT, 500-501
 prenatal, for toxoplasmosis, 337
 see also Diagnosis
- Second-trimester liver diseases, 100
- Secondary malignant neoplasms of liver in pregnancy, 172-173
- Sedation, *see* Analgesia and sedation in NICUs
- Selection of cases for experimental fetal therapy, 194-195
- SEM (skin, eye, and mouth) disease, neonatal, *see* Herpes simplex virus infections, neonatal
- Sensitivity to pain, neonatal
 analysis of, 413-414
 in premature infants, 418
- Sevoflurane, 357-358, 369, 370, 396
- Sheehan's syndrome in pregnancy, 465-466
- Side effects, *see* Adverse effects
- Signs and symptoms, *see* Clinical features and presentation
- Skin, eye, and mouth disease, neonatal, *see* Herpes simplex virus infections, neonatal
- Skin commensal species in neonatal nosocomial infections, 27-29
- Sodium thiopental (STP; thiopental), 354, 355, 395, 398
- Specificity analysis of neonatal pain, 413-414
- Spinal anesthesia, neonatal, 382-383
- Spiroglactone, 475
- Splenic artery aneurysm, as complication of cirrhosis and portal hypertension in pregnancy, 162-163
- Spontaneous abortion
 with CAH, 449
 and hypertension due to endocrine causes, 473, 480
 with parathyroid disorders, 490
 with pituitary diseases, 461
- Stimuli
 reduction of noxious, neonatal pain management with, 437
 stimulation of nonnoxious, neonatal pain management with, 439
- STP (sodium thiopental; thiopental), 354, 355, 395, 398
- Streptococcus agalactiae*, *see* Group B streptococcus infections, maternal; Group B streptococcus infections, neonatal
- Stress, defined, 417
- Subclasses of Igs and antibodies, 10-11
- Subsequent pregnancy outcome in HELLP patients, 128-130
- Succinylcholine, 356, 358, 373, 398
- Sucking, non-nutritive, in neonatal pain management, 439

- Sucrose administration, neonatal pain management with, 440
- Sufentanil, 351, 352, 358, 373, 421, 422
- Surgery
- of Cushing's syndrome, 481
 - parathyroidectomy as, 490
 - percutaneous transluminal angioplasty of renovascular hypertension, 474
 - of pheochromocytoma, 478-479
 - of prolactinoma, 458, 459
 - see also* Adrenalectomy; Neonatal anesthesia; Procedures
- Symptoms, *see* Clinical features and presentation
- Synactive theory of infant development, NIDCAP model and, 435-437
- Syncytial virus infection, *see* Respiratory syncytial virus infection, neonatal
- Syphilis in pregnancy, 323-331
- clinical presentation of, 324-326
 - congenital, 325-327
 - diagnosis of, 325-327
 - effects of, 324-325
 - therapy of, 327-329
 - transmission and pathogenesis of, 323-324
- Systemic analgesia in NICUs, 420-422
- T cell(s), neonatal, 5
- activation of, 6-9
 - cytolysis and, 7-10
 - functional response of, 8
 - helper function of, 9
- T cell receptors (TCRs), neonatal, 5
- repertoire of, 8
- Tacrolimus (FK 506) for pregnant liver transplant recipients, 151
- TCRs, *see* T cell receptors, neonatal
- Temperature regulation, *see* Thermoregulation
- Tests, *see* Laboratory evaluation
- Tetracaine, 376, 397
- Therapy and management
- of neonatal opioid withdrawal, 430-432
 - see also* Analgesia, neonatal; Care of extremely low birth weight infants; Experimentation, treatment versus; Fetal therapy; Futility of care considerations in NICUs; Nosocomial infections in NICUs; Prevention; Reproductive health, managed care of; Routine care; Surgery; Therapy and management, maternal; Therapy and management of neonatal infections
- Therapy and management, maternal
- of acromegaly, 463-464
 - of AFLP, 138
 - antiretroviral, for HIV infection, 74-79, 84, 295, 300, 302-304
 - of BV, effects of, on preterm birth and delivery, 247-248
 - of chronic active hepatitis, 115-116
 - of cirrhosis and portal hypertension, 158-161
 - of CMV infection, 265
 - of Cushing's syndrome, 481-482
 - of diabetes insipidus as, 467
 - of HELLP, 123-128
 - of HPT, 490
 - of HSV infection, 288-289
 - of 21-hydroxylase deficiency CAH, 449-450
 - of hypoparathyroidism, 491
 - of hypopituitarism, 464-465
 - of IAI, 255
 - of ICP, 107-109
 - of liver hematoma and rupture, 144-146
 - of lymphocytic hypophysitis, 465
 - of osteoporosis, 494
 - of parvovirus B19 infection, 314-316
 - of pheochromocytoma, 478-479
 - of PPT, 501
 - of primary hyperaldosteronism, 475
 - of prolactinoma, 461-463
 - of renovascular hypertension, 474
 - routine, of HIV-infected pregnant women, 73-74
 - of rubella, 319
 - of rubeola, 321-322
 - of Sheehan's syndrome as, 466
 - of syphilis, 327-329
 - of toxoplasmosis, 336-337
 - of VZV infection, 343-345
 - see also* Obstetric management; Postpartum management, maternal
- Therapy and management of neonatal infections
- of CMV infection, 265
 - of GBS infection, 33-34, 37-42, 270-273
 - of HSV infection, 69-71, 289
 - with IVIg, 57-61
 - routine care of HIV-infected neonates, 82-84
 - syphilis, 329
 - see also* Prevention of neonatal infections
- Thermoregulation
- in general anesthesia for neonatal emergency surgery, 376
 - during labor, regional anesthesia effects on maternal, 353
 - in micropremies, anesthesia and, 393
- Thiopental (sodium thiopental; STP), 354, 355, 395, 398
- Third-party interests, consideration of, following prenatal diagnosis, 192
- Third-trimester abortion, dilemma of, following prenatal diagnosis, 192-194
- Third-trimester liver diseases, 100
- Thrombotic thrombocytopenia purpura (TTP), clinical characteristics of, 120
- Thyroiditis, *see* Postpartum thyroiditis
- Thyrotropin (TSH)-secreting tumors in pregnancy, 464
- Thyroxine, 501
- Tincture of opium, 431
- Tolerance, opioid, *see* Opioid tolerance in neonates
- Topical analgesia in NICUs, 420
- Topical EMLA cream, 385-387, 419, 420
- Total cortisol, normal ranges of, in pregnancy, 447
- Toxoplasmosis, 332-338
- clinical manifestations, 333
 - diagnosis of, 333-335
 - epidemiology of, 333
 - parasitology of, 332-333
 - prenatal screening for, 337

- prognosis with, 337
therapy of, 336-337
- Transmission
of HSV infection, 287
of parvovirus B19 infection, 310
of syphilis, 323-324
see also Transmission of HIV infection and specific conditions
- Transmission of HIV infection
processes of, 299-301
via breast milk, 82, 301-302
see also Transmission of HIV infection, reducing risk of
- Transmission of HIV infection, reducing risk of, 75-79
with maternal antiretroviral therapy, 75-79, 302
with nonpharmacologic methods, 79
- Transplantation, *see* Liver transplantation, pregnancy and
- Trilostane, 481-482
- TSH (thyrotropin)-secreting tumors in pregnancy, 464
- TTP (thrombotic thrombocytopenia purpura), clinical characteristics of, 120
- d-Tubocurarine, 373
- Tumors, *see* Neoplasms in pregnancy; Pituitary disease(s) and tumor(s) in pregnancy
- Twin pregnancy, 192-195
abortion of, following prenatal diagnosis, 192-194
experimental fetal therapy in, 195
- Ultrasound
in diagnosis of fetal CAH, 453
see also specific conditions
- Unidimensional neonatal pain measures, 404-407
- Upper genital tract infections, BV and, preterm birth and delivery, 245-247
- Urinary-free cortisol, normal ranges of, in pregnancy, 447
- Urine culture, early onset neonatal bacterial infection diagnosis with, 22
- Utility and feasibility of neonatal pain measures, 403-404
multidimensional measures, 411, 412
unidimensional measures, 405
- Vaccination, *see* Immunization
- Vaginal antisepsis, prevention of neonatal GBS infections, 37
- Vaginal flora, normal, 242-243
- Vaginosis, *see* Bacterial vaginosis
- Validity of neonatal pain measures, 403
multidimensional measures, 411, 412
unidimensional measures, 405
- Variceal hemorrhages, as complications of cirrhosis and portal hypertension in pregnancy, 161
- Varicella (VZV infection), 339-346
clinical manifestations of, 340
diagnosis of, 340-341
pathogenesis of, 339-340
therapy and management of, 343-345
vaccination against, 345
varicella embryopathy, 341-342
varicella of the newborn, 343
- Varicella embryopathy, 341-342
- Varicella of newborn, 343
- Vasopressin (AVP), and water balance in pregnancy, 467
- Vecuronium, 356, 373-375
- Vertical transmission of HIV infection, *see* Transmission of HIV infection
- Viral culture for HIV diagnosis in neonates, 80, 81
- Virology
of HIV infection, 294-295
of HSV infection, 284-285
of parvovirus B19 infection, 309
- Vitamin D therapy, 490, 491, 494
- VZV infection, *see* Varicella
- Water balance, and diabetes insipidus in pregnancy, 467
- Weight, *see* Birth weight
- Wielenga Observation Scale for Pain in Neonates (WOPP; "Wielenga Observatieschaal Pijn bij Pasgeborenen"), 408, 411
- Wilson's disease (hepaticolenticular degeneration), contraception for patients with, 180
- Withdrawal, neonatal opioid
assessment of, 428-430
clinical signs of, 428
pharmacological management of, 430-432
- Withholding versus withdrawing life-sustaining care of extremely low birth weight infants, 213-214
- WOPP (Wielenga Observation Scale for Pain in Neonates; "Wielenga Observatieschaal Pijn bij Pasgeborenen") 408, 411
- Zidovudine (ZDV; Retrovir; azidothymidine) for HIV infection, 75-79, 84, 295, 300, 302-304

